Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes and Hirschsprung disease
- PMID: 7883791
- DOI: 10.1242/jcs.1994.supplement_18.6
Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes and Hirschsprung disease
Abstract
Distinct point mutations in the RET proto-oncogene are the cause of the inherited multiple endocrine neoplasia type 2 syndromes (MEN 2), and the congenital gut disorder Hirschsprung disease. The site and type of these mutations suggests that they have differing effects on the activity of the receptor tyrosine kinase encoded by RET. The normal function of the RET receptor tyrosine kinase has yet to be determined. However, this has been investigated by the inactivation of the RET gene in transgenic mice. The developmental abnormalities apparent in these mice, together with the observation that the major tissues affected in MEN 2 and Hirschsprung disease have a common origin in the embryonal neural crest, suggest that RET encodes a receptor for a developmental regulator involved in the genesis of a variety of neural crest derivatives, and in the organogenesis of the kidney.
Similar articles
-
RET mutations in multiple endocrine neoplasia type 2 and Hirschsprung disease.Curr Opin Pediatr. 1995 Dec;7(6):702-9. doi: 10.1097/00008480-199512000-00014. Curr Opin Pediatr. 1995. PMID: 8776023 Review.
-
Genetic basis of endocrine disease: multiple endocrine neoplasia type 2.J Clin Endocrinol Metab. 1995 Jul;80(7):1989-95. doi: 10.1210/jcem.80.7.7608246. J Clin Endocrinol Metab. 1995. PMID: 7608246 Review. No abstract available.
-
ret protooncogene mutations and endocrine neoplasia--a story intertwined with neural crest differentiation.Endocrinology. 1996 May;137(5):1509-11. doi: 10.1210/endo.137.5.8612478. Endocrinology. 1996. PMID: 8612478 No abstract available.
-
Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.Verh Dtsch Ges Pathol. 1995;79:L-LV. Verh Dtsch Ges Pathol. 1995. PMID: 8600671
-
RET oncogene.Curr Opin Genet Dev. 1996 Feb;6(1):82-6. doi: 10.1016/s0959-437x(96)90015-5. Curr Opin Genet Dev. 1996. PMID: 8791480 Review.
Cited by
-
Molecular rearrangements and morphology in thyroid cancer.Am J Pathol. 2002 Jun;160(6):1941-4. doi: 10.1016/S0002-9440(10)61142-X. Am J Pathol. 2002. PMID: 12057897 Free PMC article. Review. No abstract available.
-
A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells.Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7933-7. doi: 10.1073/pnas.93.15.7933. Proc Natl Acad Sci U S A. 1996. PMID: 8755580 Free PMC article.
-
RET/PTC rearrangement in thyroid tumors.Endocr Pathol. 2002 Spring;13(1):3-16. doi: 10.1385/ep:13:1:03. Endocr Pathol. 2002. PMID: 12114746 Review.
-
Molecular heterogeneity of RET loss of function in Hirschsprung's disease.EMBO J. 1996 Jun 3;15(11):2717-25. EMBO J. 1996. PMID: 8654369 Free PMC article.
-
p53 gene mutation: software and database.Nucleic Acids Res. 1996 Jan 1;24(1):147-50. doi: 10.1093/nar/24.1.147. Nucleic Acids Res. 1996. PMID: 8594565 Free PMC article.